Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2022 Filed Aug 3, 2022 12:16 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
SaleCommon Stock | 20,676 | $40.99 | $847,509.24 |
DisclosureSEC source: 0001225208-22-009143 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,485.99 Read SEC document |
| July 29, 2022 Filed Dec 14, 2022 21:37 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-012777 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,871 Read SEC document |
| July 18, 2022 Filed Jul 18, 2022 20:48 UTC |
Carruthers WendyEVP, Human Resources
|
SaleCommon Stock | 7,500 | $38.00 | $285,000.00 |
DisclosureSEC source: 0001225208-22-008824 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,913 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:56 UTC |
Monson JonathanSVP, Global Controller and CAO
|
Exercise / conversionDeferred Stock Units · Derivative | 728 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-008662 · doc4.xml · derivative · entry 3 Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 729 Underlying: Common Stock · 728 shares Expires 2023-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2020, the first anniversary of the date of grant. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:56 UTC |
Monson JonathanSVP, Global Controller and CAO
|
Tax withholdingCommon Stock | 214 | $38.01 | $8,134.14 |
DisclosureSEC source: 0001225208-22-008662 · doc4.xml · nonDerivative · entry 2 Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,833 Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:56 UTC |
Monson JonathanSVP, Global Controller and CAO
|
Exercise / conversionCommon Stock | 728 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-008662 · doc4.xml · nonDerivative · entry 1 Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:55 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Exercise / conversionRestricted Stock Units · Derivative | 4,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-008661 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,108 Underlying: Common Stock · 4,035 shares Expires 2025-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2022, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2022, the first anniversary of the date of grant. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:55 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Tax withholdingCommon Stock | 1,185 | $38.01 | $45,041.85 |
DisclosureSEC source: 0001225208-22-008661 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,605 Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:55 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Exercise / conversionCommon Stock | 4,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-008661 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| June 24, 2022 Filed Jun 27, 2022 20:27 UTC |
Carruthers WendyEVP, Human Resources
|
SaleCommon Stock | 7,500 | $38.00 | $285,000.00 |
DisclosureSEC source: 0001225208-22-008300 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,413 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| May 16, 2022 Filed May 17, 2022 20:37 UTC |
Carruthers WendyEVP, Human Resources
|
SaleCommon Stock | 7,500 | $39.43 | $295,725.00 |
DisclosureSEC source: 0001225208-22-007121 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,913 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| May 16, 2022 Filed Dec 5, 2022 21:20 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
GiftCommon Stock | 26 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-012296 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,290 Read SEC document |
| May 05, 2022 Filed May 6, 2022 21:08 UTC |
Zane Ellen MDirector
|
GrantCommon Stock | 4,877 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006635 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,683 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 05, 2022 Filed May 6, 2022 21:08 UTC |
WICHMANN DAVID SDirector
|
GrantCommon Stock | 2,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006634 · doc4.xml · nonDerivative · entry 2 WICHMANN DAVID S · CIK 0001268489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,613 F2 · shares: Restricted stock granted in lieu of 100% of cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of $115,000, divided by the closing price of common stock on the date of grant. Read SEC document |
| May 05, 2022 Filed May 6, 2022 21:08 UTC |
WICHMANN DAVID SDirector
|
GrantCommon Stock | 4,877 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006634 · doc4.xml · nonDerivative · entry 1 WICHMANN DAVID S · CIK 0001268489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,877 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 05, 2022 Filed May 6, 2022 21:08 UTC |
Sununu John EDirector
|
GrantCommon Stock | 4,877 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006633 · doc4.xml · nonDerivative · entry 1 Sununu John E · CIK 0001458974 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,795 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 05, 2022 Filed May 6, 2022 21:08 UTC |
ROUX DAVID JDirector
|
GrantCommon Stock | 4,877 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006632 · doc4.xml · nonDerivative · entry 1 ROUX DAVID J · CIK 0001234273 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,645 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 05, 2022 Filed May 6, 2022 21:06 UTC |
JAMES DONNADirector
|
GrantDeferred Stock Units · Derivative | 4,877 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006630 · doc4.xml · derivative · entry 1 JAMES DONNA · CIK 0001197735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,124 Underlying: Common Stock · 4,877 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: Reflects a value of $205,000 divided by the closing price of common stock on the date of grant. F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 05, 2022 Filed May 6, 2022 21:08 UTC |
LUDWIG EDWARD JDirector
|
GrantCommon Stock | 4,877 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006631 · doc4.xml · nonDerivative · entry 1 LUDWIG EDWARD J · CIK 0001221783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,374 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 05, 2022 Filed May 6, 2022 21:06 UTC |
FUJIMORI YOSHIAKIDirector
|
GrantDeferred Stock Units · Derivative | 4,877 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006629 · doc4.xml · derivative · entry 1 FUJIMORI YOSHIAKI · CIK 0001233160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,751 Underlying: Common Stock · 4,877 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: Reflects a value of $205,000 divided by the closing price of common stock on the date of grant. F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 05, 2022 Filed May 6, 2022 21:06 UTC |
Connors Nelda JDirector
|
GrantCommon Stock | 4,877 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006628 · doc4.xml · nonDerivative · entry 1 Connors Nelda J · CIK 0001478748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,965 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 05, 2022 Filed May 9, 2022 20:27 UTC |
Dockendorff Charles JDirector
|
GrantCommon Stock | 4,877 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006716 · doc4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,079 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 02, 2022 Filed Sep 1, 2022 20:24 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
GrantStock Option (Right to Buy) · Derivative | 22,267 | $0.00 Strike: $41.63 | $0.00 |
DisclosureSEC source: 0001225208-22-009905 · doc4.xml · derivative · entry 2 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,267 Underlying: Common Stock · 22,267 shares Expires 2032-05-02 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant. Read SEC document |
| May 02, 2022 Filed Sep 1, 2022 20:24 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
GrantRestricted Stock Units · Derivative | 8,407 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-009905 · doc4.xml · derivative · entry 1 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,407 Underlying: Common Stock · 8,407 shares Expires 2026-05-02 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant. Read SEC document |
| May 02, 2022 Filed Sep 1, 2022 20:23 UTC |
Sorenson John BradleyEVP, Global Operations
|
GrantRestricted Stock Units · Derivative | 16,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-009904 · doc4.xml · derivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,814 Underlying: Common Stock · 16,814 shares Expires 2026-05-02 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's committment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant. Read SEC document |
| May 01, 2022 Filed May 2, 2022 20:33 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
Exercise / conversionDeferred Stock Units · Derivative | 2,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006331 · doc4.xml · derivative · entry 3 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,062 Underlying: Common Stock · 2,062 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 1, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 1, 2020, the first anniversary of the date of grant. Read SEC document |
| May 01, 2022 Filed May 2, 2022 20:33 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
Tax withholdingCommon Stock | 606 | $42.11 | $25,518.66 |
DisclosureSEC source: 0001225208-22-006331 · doc4.xml · nonDerivative · entry 2 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,461 Read SEC document |
| May 01, 2022 Filed May 2, 2022 20:33 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
Exercise / conversionCommon Stock | 2,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006331 · doc4.xml · nonDerivative · entry 1 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| April 20, 2022 Filed Apr 21, 2022 20:26 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
SaleCommon Stock | 9,645 | $46.50 | $448,492.50 |
DisclosureSEC source: 0001225208-22-005987 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,316 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| April 19, 2022 Filed Apr 20, 2022 20:52 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
SaleCommon Stock | 10,989 | $45.50 | $499,999.50 |
DisclosureSEC source: 0001225208-22-005929 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,961 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| April 14, 2022 Filed Apr 14, 2022 20:37 UTC |
Carruthers WendyEVP, Human Resources
|
SaleCommon Stock | 7,500 | $44.47 | $333,518.25 |
DisclosureSEC source: 0001225208-22-005838 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,413 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $44.22 to $44.64, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 1, 2022 20:27 UTC |
Olson ScottSVP & Pres, CRM, Diagnostics
|
SaleCommon Stock | 700 | $44.55 | $31,185.00 |
DisclosureSEC source: 0001225208-22-005306 · doc4.xml · nonDerivative · entry 1 Olson Scott · CIK 0001816850 · SVP & Pres, CRM, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,518 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:21 UTC |
Eddy Jodi EuerleSVP, Chief Info & Digital Off.
|
SaleCommon Stock | 2,779 | $45.00 | $125,055.00 |
DisclosureSEC source: 0001225208-22-005398 · doc4.xml · nonDerivative · entry 1 Eddy Jodi Euerle · CIK 0001734900 · SVP, Chief Info & Digital Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,263 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 20:31 UTC |
Butcher Arthur CEVP&Pres, Asia Pacific
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,411 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001225208-22-005267 · doc4.xml · derivative · entry 4 Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,822 Underlying: Common Stock · 5,411 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 20:31 UTC |
Butcher Arthur CEVP&Pres, Asia Pacific
|
SaleCommon Stock | 10,269 | $45.00 | $462,105.00 |
DisclosureSEC source: 0001225208-22-005267 · doc4.xml · nonDerivative · entry 2 Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,278 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 20:31 UTC |
Butcher Arthur CEVP&Pres, Asia Pacific
|
Exercise / conversionCommon Stock | 5,411 | $16.31 | $88,253.41 |
DisclosureSEC source: 0001225208-22-005267 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 28, 2022 Filed Mar 29, 2022 20:45 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
SaleCommon Stock | 6,588 | $43.68 | $287,763.84 |
DisclosureSEC source: 0001225208-22-005192 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,082 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 20:20 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
SaleCommon Stock | 11,236 | $44.50 | $500,002.00 |
DisclosureSEC source: 0001225208-22-004996 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,950 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 20:25 UTC |
Carruthers WendyEVP, Human Resources
|
SaleCommon Stock | 7,500 | $42.34 | $317,586.75 |
DisclosureSEC source: 0001225208-22-004768 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,913 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.14 to $42.59, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:21 UTC |
Fitzgerald Joseph MichaelEVP & Pres, Cardiology
|
Exercise / conversionDeferred Stock Units · Derivative | 3,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-004296 · doc4.xml · derivative · entry 5 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,603 shares Expires 2022-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:21 UTC |
Fitzgerald Joseph MichaelEVP & Pres, Cardiology
|
Tax withholdingCommon Stock | 1,779 | $43.96 | $78,204.84 |
DisclosureSEC source: 0001225208-22-004296 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,871 Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:21 UTC |
Fitzgerald Joseph MichaelEVP & Pres, Cardiology
|
Exercise / conversionCommon Stock | 3,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-004296 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 21:24 UTC |
Brennan Daniel J.EVP and CFO
|
SaleCommon Stock | 11,029 | $44.03 | $485,649.88 |
DisclosureSEC source: 0001225208-22-004108 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,290 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.71 to $44.43, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 21:29 UTC |
Pierce David AEVP Pres MedSurg
|
SaleCommon Stock | 1,726 | $43.94 | $75,840.44 |
DisclosureSEC source: 0001225208-22-003867 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:29 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
Exercise / conversionDeferred Stock Units · Derivative | 1,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003868 · doc4.xml · derivative · entry 3 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,019 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:29 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
Tax withholdingCommon Stock | 300 | $44.17 | $13,251.00 |
DisclosureSEC source: 0001225208-22-003868 · doc4.xml · nonDerivative · entry 2 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,005 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:29 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
Exercise / conversionCommon Stock | 1,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003868 · doc4.xml · nonDerivative · entry 1 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:29 UTC |
Olson ScottSVP & Pres, CRM, Diagnostics
|
Exercise / conversionDeferred Stock Units · Derivative | 1,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003866 · doc4.xml · derivative · entry 3 Olson Scott · CIK 0001816850 · SVP & Pres, CRM, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,426 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:29 UTC |
Olson ScottSVP & Pres, CRM, Diagnostics
|
Tax withholdingCommon Stock | 766 | $44.17 | $33,834.22 |
DisclosureSEC source: 0001225208-22-003866 · doc4.xml · nonDerivative · entry 2 Olson Scott · CIK 0001816850 · SVP & Pres, CRM, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,218 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:29 UTC |
Olson ScottSVP & Pres, CRM, Diagnostics
|
Exercise / conversionCommon Stock | 1,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003866 · doc4.xml · nonDerivative · entry 1 Olson Scott · CIK 0001816850 · SVP & Pres, CRM, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.